We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
Read MoreHide Full Article
Key Takeaways
UnitedHealth faces a Q3 test of whether its second-quarter medical-cost improvement can continue.
UnitedHealth's Q2 MCR improved to 86.7%, helped by $860 million of favorable reserve development.
UNH expects Medicare margins above 3% in 2026 as MA membership losses roughly 1.1 million.
UnitedHealth Group Incorporated (UNH - Free Report) heads into third-quarter earnings on Oct. 13 with a different test than it faced earlier this year. The focus is no longer simply on whether results are improving. Investors now want to know whether the second-quarter rebound can hold.
Medical Costs: Is the Improvement Sustainable?
UnitedHealthcare’s MCR improved to 86.7% in the second quarter from 89.4% a year earlier. Operating earnings rose to $3.9 billion from $2.1 billion, while operating margin climbed to 4.6% from 2.4%. Still, the quarter included $860 million of favorable medical reserve development, which helped the reported improvement.
That leaves investors looking for cleaner evidence in the third quarter. Key areas include underlying medical costs, Medicare inpatient and outpatient utilization, commercial cost trends, specialty-drug inflation and provider coding intensity. Management’s 88.1% full-year MCR outlook will also be closely watched.
Can MA Margins Improve Without More Member Losses?
The second major question is whether UnitedHealthcare can repair Medicare Advantage profitability without giving up too much enrollment.
MA membership stood at 7.565 million at June 30, down 785,000 from a year earlier. Including certain complex populations, senior enrollment had fallen by about 965,000 since 2025-end. Management expects the full-year MA decline to reach roughly 1.1 million members.
Some of that pressure is intentional. UNH has been adjusting benefits, pricing, networks and market exposure to improve returns. Management still expects Medicare margins to finish 2026 above 3%.
The third quarter will show whether the trade-off is working. Investors will be watching enrollment, retention, benefit changes for 2027 and any update to the attrition forecast. A smaller, healthier Medicare book could support earnings, but deeper membership losses would raise fresh concerns about growth. The strongest outcome would pair steadier medical costs with improving Medicare economics and member retention.
How are Peers Placed?
Peers like Humana Inc. (HUM - Free Report) and Elevance Health, Inc. (ELV - Free Report) are also fighting rising medical cost trends. Neither Humana nor Elevance Health showed year-over-year cost-ratio improvement in the last reported quarter. Humana’s Insurance benefit ratio rose to 91.2% from 89.9%, up 130 basis points, despite some inpatient favorability. Elevance’s benefit expense ratio increased to 89.7% from 88.9%, up 80 basis points, mainly reflecting elevated medical costs in its Government businesses, partly offset by better ACA performance.
UnitedHealth’s Price Performance, Valuation and Estimates
Shares of UNH have gained 15.1% in the year-to-date period compared with the industry’s growth of 16.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 17.28, up from the industry average of 15.20. UNH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $19.85 per share, implying a 21.4% improvement from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) heads into third-quarter earnings on Oct. 13 with a different test than it faced earlier this year. The focus is no longer simply on whether results are improving. Investors now want to know whether the second-quarter rebound can hold.
Medical Costs: Is the Improvement Sustainable?
UnitedHealthcare’s MCR improved to 86.7% in the second quarter from 89.4% a year earlier. Operating earnings rose to $3.9 billion from $2.1 billion, while operating margin climbed to 4.6% from 2.4%. Still, the quarter included $860 million of favorable medical reserve development, which helped the reported improvement.
That leaves investors looking for cleaner evidence in the third quarter. Key areas include underlying medical costs, Medicare inpatient and outpatient utilization, commercial cost trends, specialty-drug inflation and provider coding intensity. Management’s 88.1% full-year MCR outlook will also be closely watched.
Can MA Margins Improve Without More Member Losses?
The second major question is whether UnitedHealthcare can repair Medicare Advantage profitability without giving up too much enrollment.
MA membership stood at 7.565 million at June 30, down 785,000 from a year earlier. Including certain complex populations, senior enrollment had fallen by about 965,000 since 2025-end. Management expects the full-year MA decline to reach roughly 1.1 million members.
Some of that pressure is intentional. UNH has been adjusting benefits, pricing, networks and market exposure to improve returns. Management still expects Medicare margins to finish 2026 above 3%.
The third quarter will show whether the trade-off is working. Investors will be watching enrollment, retention, benefit changes for 2027 and any update to the attrition forecast. A smaller, healthier Medicare book could support earnings, but deeper membership losses would raise fresh concerns about growth. The strongest outcome would pair steadier medical costs with improving Medicare economics and member retention.
How are Peers Placed?
Peers like Humana Inc. (HUM - Free Report) and Elevance Health, Inc. (ELV - Free Report) are also fighting rising medical cost trends. Neither Humana nor Elevance Health showed year-over-year cost-ratio improvement in the last reported quarter. Humana’s Insurance benefit ratio rose to 91.2% from 89.9%, up 130 basis points, despite some inpatient favorability. Elevance’s benefit expense ratio increased to 89.7% from 88.9%, up 80 basis points, mainly reflecting elevated medical costs in its Government businesses, partly offset by better ACA performance.
UnitedHealth’s Price Performance, Valuation and Estimates
Shares of UNH have gained 15.1% in the year-to-date period compared with the industry’s growth of 16.7%.
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 17.28, up from the industry average of 15.20. UNH carries a Value Score of A.
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $19.85 per share, implying a 21.4% improvement from the year-ago period.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.